Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
| Revenue (Most Recent Fiscal Year) | $30.09B |
| Net Income (Most Recent Fiscal Year) | $712.33M |
| PE Ratio (Current Year Earnings Estimate) | 8.65 |
| PE Ratio (Trailing 12 Months) | 9.37 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.57 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.65 |
| Pre-Tax Margin (Trailing 12 Months) | 3.82% |
| Net Margin (Trailing 12 Months) | 2.36% |
| Return on Equity (Trailing 12 Months) | 10.64% |
| Return on Assets (Trailing 12 Months) | 5.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.57 |
| Inventory Turnover (Trailing 12 Months) | 1.28 |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.39 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.16 |
| Earnings per Share (Most Recent Fiscal Year) | $1.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.22 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 3.18B |
| Free Float | 3.18B |
| Market Capitalization | $47.09B |
| Average Volume (Last 20 Days) | 2.14M |
| Beta (Past 60 Months) | 0.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.04% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.17% |
| Annual Dividend (Based on Last Quarter) | $0.53 |
| Dividend Yield (Based on Last Quarter) | 3.61% |